Site specific biotinylated antibody functionalized Ag@AuNIs LSPR biosensor for the ultrasensitive detection of exosomal MCT4, a glioblastoma progression biomarker
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Author(s)
Related Research Unit(s)
Detail(s)
Original language | English |
---|---|
Article number | 137383 |
Journal / Publication | Chemical Engineering Journal |
Volume | 446 |
Issue number | Part 4 |
Online published | 6 Jun 2022 |
Publication status | Published - 15 Oct 2022 |
Link(s)
DOI | DOI |
---|---|
Attachment(s) | Documents
Publisher's Copyright Statement
|
Link to Scopus | https://www.scopus.com/record/display.uri?eid=2-s2.0-85132398209&origin=recordpage |
Permanent Link | https://scholars.cityu.edu.hk/en/publications/publication(5e315281-a770-4fb0-9f40-45f1f906c5bc).html |
Abstract
Glioblastoma (GBM) is an incurable brain tumor in which hypoxic GBM cells (GMs) increase the production and release of exosomes, which are 30–200 nm vesicles crossing the blood–brain-barrier, enabling exosomal biomarkers to be promising targets for the tracking of GBM malignancy. Here, a localized surface plasmon resonance (LSPR) sensor chip was developed to detect an infinitesimal amount of exosomal biomarkers. Self-assembly silver nanoparticles decorated on gold nano-islands (Ag@AuNIs) sensor chip was used to provide site-specific bio-conjunction of biotinylated antibodies for detection of exosomal surface biomarkers. The biotinylated antibody functionalized (BAF) Ag@AuNIs LSPR biosensor sensitively detected cluster of differentiation 63, an exosome marker, and monocarboxylate transporter 4 (MCT4), a GBM progression biomarker, in malignant GMs-derived exosomes in the dynamic range of 3.8 × 10−4 to 50 μg/ml with limit of detection (LOD) of 0.38 ng/ml and 1.4 × 10−3 to 500 μg/ml with LOD of 1.4 ng/ml, respectively. Furthermore, it detected the enhanced level of MCT4 in malignant hypoxic GMs-derived exosomes as well as increased MCT4 in the blood serum-derived exosomes of GBM mice in the dynamic range of 4 × 10−4 to 50 μg/ml with LOD of 0.4 ng/ml. Finally, it could quantify MCT4 in the isolated GMs-derived exosomes from the blood of GBM mice by epidermal growth factor receptor variant III-based immunocapture, suggesting its utility for minimally-invasive monitoring of GBM progression as liquid biopsy. With excellent attributes of high sensitivity and selectivity in label-free sensing for exosomal biomarkers, the BAF Ag@AuNIs LSPR biosensor has great potential for early detection of GBM formation and progression.
Research Area(s)
- Biosensor, Plasmonics, Glioblastoma, Exosome, MCT4, Liquid biopsy
Citation Format(s)
Site specific biotinylated antibody functionalized Ag@AuNIs LSPR biosensor for the ultrasensitive detection of exosomal MCT4, a glioblastoma progression biomarker. / Liu, Linlin; Thakur, Abhimanyu; Li, Wing Kar et al.
In: Chemical Engineering Journal, Vol. 446, No. Part 4, 137383, 15.10.2022.
In: Chemical Engineering Journal, Vol. 446, No. Part 4, 137383, 15.10.2022.
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Download Statistics
No data available